Sarepta Therapeutics announced it will not enroll additional patients in the confirmatory Phase 3 trial of Elevidys, its Duchenne muscular dystrophy gene therapy, a study required to maintain the drug's accelerated approval.
Cigna raised its annual profit forecast after beating third-quarter results, driven by gains in its specialty-pharmacy and health-services businesses, though its pharmacy benefits manager Express Scripts remains a drag.
Novo Nordisk raised its full-year forecast for the third time in 2026 after third-quarter sales of its Wegovy weight-loss pill reached $807 million, beating analyst expectations and driving stronger-than-expected quarterly earnings.
Israeli drugmaker Teva Pharmaceutical Industries reported third-quarter profit that exceeded analyst expectations, driven by strong sales of three branded medicines that offset declines in generic drugs. The company raised its full-year 2026 revenue estimates following the results.
Indian drugmaker Cipla reported second-quarter earnings that missed profit expectations due to weakness in its US business, causing its shares to decline. The disappointing results reflect challenges in the company's American operations.
Novartis increased its full-year core profit outlook for the third time in 2026, driven by growth of new medicines, but took a $1.9 billion write-down for neuromuscular drug candidate del-desiran following trial failure.